Community Bank N.A. Sells 6,168 Shares of Pfizer Inc. $PFE

Community Bank N.A. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,580 shares of the biopharmaceutical company’s stock after selling 6,168 shares during the period. Community Bank N.A.’s holdings in Pfizer were worth $2,025,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital Advisory Group Advisory Services LLC raised its position in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 388 shares during the last quarter. Citizens National Bank Trust Department raised its position in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares in the last quarter. Trust Co of the South raised its position in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares in the last quarter. Charter Oak Capital Management LLC raised its position in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 444 shares in the last quarter. Finally, Ballentine Partners LLC raised its position in shares of Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after acquiring an additional 458 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.3%

PFE stock opened at $24.72 on Tuesday. The business has a 50 day moving average of $24.88 and a 200 day moving average of $24.12. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.82. The firm has a market cap of $140.52 billion, a PE ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business posted $0.60 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.